Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Solara Active Pharma Sciences's PB Ratio or its related term are showing as below:
NSE:SOLARA'
s PB Ratio Range Over the Past 10 Years
Min: 0.76 Med: 1.75 Max: 4
Current: 2.2
During the past 10 years, Solara Active Pharma Sciences's highest PB Ratio was 4.00. The lowest was 0.76. And the median was 1.75.
NSE:SOLARA's PB Ratio is ranked worse than 55.63% of 924
companies
in the Drug Manufacturers industry
Industry Median: 1.895
vs NSE:SOLARA: 2.20
During the past 12 months, Solara Active Pharma Sciences's average Book Value Per Share Growth Rate was 14.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -12.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -11.70% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Solara Active Pharma Sciences was 12.60% per year. The lowest was -16.40% per year. And the median was -5.60% per year.
Back to Basics: PB Ratio
Solara Active Pharma Sciences (NSE:SOLARA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Solara Active Pharma Sciences PB Ratio Related Terms
Solara Active Pharma Sciences PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Solara Active Pharma Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solara Active Pharma Sciences PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Solara Active Pharma Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Solara Active Pharma Sciences's PB Ratio falls into.
Solara Active Pharma Sciences PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Solara Active Pharma Sciences (NSE:SOLARA) has a PB Ratio of 2.19 as of Jul. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Solara Active Pharma Sciences and its competitors. This is 25% above median its historical median of 1.75. Over the past decade, Solara Active Pharma Sciences' PB Ratio has ranged from 0.76 to 4.00. According to the industry distribution chart, Solara Active Pharma Sciences ranks #514 out of 924 companies in the Drug Manufacturers industry, placing it in the top 55.6%.
Is Solara Active Pharma Sciences' PB Ratio too high?
Solara Active Pharma Sciences' current PB Ratio of 2.19 is 25% above median its 10-year median of 1.75. Over the past 10 years, this metric has ranged from a low of 0.76 to a high of 4.00. The Drug Manufacturers industry median PB Ratio is 1.90. Solara Active Pharma Sciences' value of 2.19 is 15.6% above this industry median. Based on the distribution chart, Solara Active Pharma Sciences ranks #514 out of 924 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Solara Active Pharma Sciences has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Solara Active Pharma Sciences' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Solara Active Pharma Sciences ranks #514 out of 924 companies for PB Ratio. This places Solara Active Pharma Sciences in the lower half of its industry. The industry median PB Ratio is 1.90. Solara Active Pharma Sciences' value of 2.19 is 15.6% above this benchmark. Historically, Solara Active Pharma Sciences' own PB Ratio has ranged from 0.76 to 4.00 over the past decade. While the company's 10-year median is 1.75 vs. the industry median of 1.90, Solara Active Pharma Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solara Active Pharma Sciences's current PB Ratio of 2.19 is 15.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Solara Active Pharma Sciences and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solara Active Pharma Sciences's current PB Ratio is 2.19, which is 25% above median its own 10-year median of 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solara Active Pharma Sciences stock overvalued right now?
Based on GuruFocus' analysis, Solara Active Pharma Sciences (NSE:SOLARA) is currently considered Fairly Valued. The stock's GF Value™ is ₹572.34, compared to a current price of ₹570.80 — trading 0.3% below its estimated fair value. The current PB Ratio is 2.19, which is 25% above median its 10-year median of 1.75 and 15.6% above the Drug Manufacturers industry median of 1.90. Solara Active Pharma Sciences' overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Solara Active Pharma Sciences (NSE:SOLARA), the current PB Ratio is 2.19 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solara Active Pharma Sciences (NSE:SOLARA) Overvalued in 2026?
Based on GuruFocus' analysis, Solara Active Pharma Sciences stock appears to be undervalued.
The current stock price of ₹570.80 is trading 0.3% below its estimated GF Value™ of ₹572.34.
GuruFocus considers Solara Active Pharma Sciences to be Fairly Valued.
Key valuation signals for NSE:SOLARA:
PB Ratio: 2.19 (25% above median its 10-year median of 1.75)
GF Value™: ₹572.34 vs. price of ₹570.80 (0.3% below fair value)
Industry Position: 15.6% above the Drug Manufacturers median (#514 of 924)
No single metric tells the full story. See the NSE:SOLARA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Solara Active Pharma Sciences Business Description
Solara Active Pharma Sciences Ltd is engaged in the Active Pharmaceutical Ingredients (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinoid, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant, and others. It also offers contract services, including contract development and manufacturing, and analytical services. Geographically, the company generates all of its revenue from India.
68GF Score
Get the complete analysis for NSE:SOLARA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOLARA has been successfully added to your 
